Wired News – CASI Pharma Purchased abbreviated new drug applications Portfolio from Sandoz

LONDON, UK / ACCESSWIRE / January 30, 2018 / Active-Investors.com has just released a free research report on CASI Pharmaceuticals, Inc. (NASDAQ: CASI). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CASI as the Company’s latest news hit the wire. On January 26, 2018, the Company declared that it has acquired a portfolio of abbreviated new drug applications (ANDAs) from Sandoz Inc. The portfolio includes 25 ANDAs approved by the US Food and Drug Administration (FDA), one ANDA that FDA tentatively approved, and three ANDAs that are pending FDA approval. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, CASI Pharmaceuticals most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CASI

Acquisition Likely to Enhance CASI Pharma’s Strategic Focus to Commercialize Quality Drug Candidates in China

The Company intends to select and commercialize certain products from the portfolio that have unique market opportunity and cost-effective manufacturing in China and/or in the US. The acquisition will enhance CASI Pharma’s strategic focus to build a robust pipeline. The Company will transfer a select subset of products from the portfolio to lower cost manufacturing facilities in China and contemplates submitting CBE-30 supplement or Prior Approval Supplement (PAS) to the approved/pending ANDAs as soon as possible.

The acquired application also includes entecavir, an antiviral medication used in the treatment of hepatitis B viral infection (HBV), which in China accounts for more than half of the estimated 700,000 HBV-related deaths worldwide each year. CASI Pharma also intends to develop and market on its own priority products from the portfolio and may partner the remaining US ANDA assets to strategic partners.

CASI Pharma to Launch Certain Products Acquired from Sandoz’s Portfolio in China

Ken Ren, Ph.D., Chief Executive Officer of CASI Pharma, stated that with FDA-approved ANDA status and the high-quality standards of Sandoz, the Company anticipates leveraging the Chinese FDA’s (CFDA) more recent regulations to accept western pharmaceutical and clinical data for rapid entry into China’s market while being competitive in the marketplace. Ken added that this is an exciting and unprecedented time in the CFDA regulatory landscape, against a backdrop of soaring demand in China for high quality import pharmaceuticals. The Company is confident in its ability to launch certain products in China that it has acquired from the Sandoz portfolio, along with its launch of EVOMELA®, MARQIBO®, and ZEVALIN® all of which are in various stages of CFDA review.

About FDA-Approved Abbreviated New Drug Application

ANDA contains data which is submitted to FDA for the review and potential approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, lower cost alternative to the brand-name drug it references.

About CASI Pharmaceuticals, Inc.

Founded in 1991, CASI Pharma is a biopharmaceutical company focused on the acquisition, development, and commercialization of quality pharmaceuticals and innovative therapeutics addressing CANCER and other unmet medical needs for the global market, with a focus on greater China and the US. The Company is headquartered in Rockville, Maryland.

About Sandoz Inc.

Established in 1886 and based in Holzkirchen, Bavaria, Sandoz (formerly known as Geneva Pharmaceuticals Technology Corporation) is a global leader in generic pharmaceuticals and biosimilars. The Company is a subsidiary of Novartis Group.

Stock Performance Snapshot

January 29, 2018 – At Monday’s closing bell, CASI Pharmaceuticals’ stock climbed 6.46%, ending the trading session at $4.12.

Volume traded for the day: 525.61 thousand shares, which was above the 3-month average volume of 489.53 thousand shares.

Stock performance in the last month – up 29.15%; previous three-month period – up 100.00%; past twelve-month period – up 188.11%; and year-to-date – up 26.77%

After yesterday’s close, CASI Pharmaceuticals’ market cap was at $268.05 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 487354